Drug firm Lyka Labs has entered into a technology transfer pact with a Turkish pharma firm for adopting a manufacturing process that enables longer storage of medicines, entailing a cost of $250,000 and royalty payments for five years.
"The company has recently entered into a technology transfer agreement with a pharma company based in Republic of Turkey for a lyophilised formulation, for a consideration of $250,000 and Royalty for five years," Lyka Labs said in a filing to BSE.
Lyophilization is a manufacturing process that helps pharmaceuticals to be stored for a long period without the degradation in materials.
The company had also entered into a technical assistance agreement for lyophilized formulations with a company based at Indonesia in November.
Shares of Lyka Labs were today trading at Rs 9.43 in the after noon trade on BSE, up 3.63% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app